Trump order boosts psychedelics reviews, stirs markets today

Psychedelics research gets a White House push as Trump’s April order speeds FDA reviews, lifting stocks while concerns over safety and study design remain.

President Donald Trump signed an executive order in April 2026 to accelerate research into psychedelic drugs for mental illness, a marked shift from his prior tougher posture on controlled substances. The plan includes incentives aimed at moving promising treatments through parts of the U.S. regulatory process faster.

At the heart of the move are priority review vouchers for companies advancing psychedelic or MDMA-like therapies, a signal that quickly drew investors. Shares of sector players, including Compass Pathways, rallied on the prospect of shorter timelines.

What the order changes

Priority review can trim FDA clock time for certain applications, but it does not guarantee approval. The policy spotlights compounds often paired with specific conditions in studies: psilocybin for depression, MDMA for PTSD, and LSD for anxiety.

Although MDMA is technically an empathogen, it is frequently discussed alongside psychedelics in therapy settings. Researchers, including Brandon Weiss of Johns Hopkins University, caution that each drug has distinct risk profiles; ibogaine stands out for notable cardiovascular risks and limited large-scale U.S. data.

Industry leaders framed the order as validation, not a shortcut. Compass Pathways CEO Kabir Nath has emphasized adherence to FDA standards, adding that companies still need robust evidence before considering any approval bid.

Evidence, safety, and FDA caution

Trials sponsored by groups such as the Multidisciplinary Association for Psychedelic Studies have reported meaningful improvements in PTSD symptoms following MDMA-assisted therapy. Yet the FDA declined an MDMA-assisted therapy application in 2024, citing concerns about trial design and the need for stronger data.

Psychedelic-assisted care is not a simple prescription. Protocols typically include preparation sessions, closely monitored dosing days, and integration therapy afterward. Acute reactions—panic, paranoia—can occur, and clinicians sometimes use rescue medications to manage severe responses.

Individual experiences vary widely. Patient accounts, like that of Marie Phelan after MDMA-assisted therapy for PTSD, describe deep emotional processing and relief, underscoring both the potential and the need for careful screening and supervision.

Global momentum and political undertones

Internationally, Australia in 2023 authorized qualified psychiatrists to prescribe MDMA and psilocybin for certain conditions, while Canada, Switzerland, and the U.K. have expanded clinical research. These moves set comparative baselines as the U.S. retools its own approach.

Some researchers warn political momentum could outpace scientific rigor if standards loosen. Veterans’ advocates, including Juliana Mercer of Healing Breakthrough, view the order as long-sought acknowledgment, even as critics question the timing and suggest an eye toward shoring up veteran support ahead of midterms.

Executives note that several programs were already approaching late-stage milestones, implying the FDA’s course might have progressed regardless. For investors, the order is a confidence cue; for regulators, it is a directive to move faster without lowering the bar.

What comes next will hinge on FDA guidance, how vouchers are deployed, and forthcoming late-stage readouts in PTSD and depression. From Washington to Taksim, the signal is clear: access and safety will be tested side by side in the months ahead.